Shares up 16 percent: Novo-Nordisk rival Eli Lilly with breakthrough in AI and cancer research
The US pharmaceutical giant is opening its market to external partners with a new AI platform. The company also announced breakthroughs with its drugs Jaypirca and Olomorasib.
Summarized for you
US drugmaker Eli Lilly announced that it is launching an AI and machine learning platform that will provide biotech companies with access to drug discovery models. Lilly's new AI platform, called TuneLab, consists of AI models acquired with a value of over $1 billion. With the new platform, Lilly is opening up its billion-dollar AI models to external partners.
The drugmaker also achieved breakthroughs in cancer research. Positive Phase 3 data for Jaypirca, a drug for blood cancer, could establish the drug as a first-line therapy. This would significantly expand the addressable market and represent potential billions in revenue.
Long
Short
wallstreetONLINE Editorial Team
0 followersShow more
Show more
Written by 
Paul Späthling
wallstreet-online
